Abstracts tagged "glucocorticoids"

Abstract Number: 412 • 2016 ACR/ARHP Annual Meeting
Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder
Daniel B. Horton¹, Fenglong Xie², Lang Chen², Melissa Mannion³, Brian L. Strom^4,5, Jeffrey Curtis⁶ and Timothy Beukelman⁷, ¹Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Diabetes mellitus (DM) and hypertension (HTN) are well-known toxicities of glucocorticoids (GCs), but the risks of these complications are unclear in children with JIA.…
Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Rachel Black¹, Susan M. Goodman², Carlee Ruediger³, Susan Lester⁴, Sarah Mackie⁵ and Catherine Hill³, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Medicine, Hospital for Special Surgery, New York, NY, ³Medicine, The University of Adelaide, Adelaide, Australia, ⁴Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
Abstract Number: 794 • 2016 ACR/ARHP Annual Meeting
Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
Zahi Touma¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: It is challenging to describe disease activity in SLE in the context of multiple levels of glucocorticoids (GC) treatment. We aim to develop and…
Abstract Number: 977 • 2016 ACR/ARHP Annual Meeting
Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study
Maxime Samson¹, Hervé Devilliers², Kim Heang Ly³, Francois Maurier⁴, Boris Bienvenu⁵, Benjamin Terrier⁶, Pierre Charles⁷, Jean-François Besancenot², Anne-Laure Fauchais⁸, Christine Binquet⁹, Sylvain Audia¹⁰ and Bernard Bonnotte¹, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Internal Medicine, University Hospital of Limoges, Limoges, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Caen University Hospital, Caen, France, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁸Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁹INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis usually treated with glucocorticoids (GC). GC are effective but responsible for substantial morbidity and mortality. Tocilizumab…
Abstract Number: 1123 • 2016 ACR/ARHP Annual Meeting
Targeted Mutations Identify the Active Site of Glucocorticoid-Induced Leucine Zipper (GILZ)
Huapeng Fan¹, Die Wang², Qiang Cheng³, James Harris³, Sarah Jones³, Yuan Hang Yang⁴ and Eric Morand⁴, ¹Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Calyton, Australia, ²Hudson Institute of Medical Research, Clayton, Australia, ³Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia, ⁴Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) have been used to treat inflammatory disease for more than six decades, but the broad spectrum of therapeutic effects is accompanied by…
Abstract Number: 1646 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies
Roy Fleischmann¹, Jürgen Wollenhaupt², Stanley Cohen¹, Michael Weinblatt³, Lisy Wang⁴, Haiyun Fan⁵, John Andrews⁶, Liza Takiya⁵ and Eustratios Bananis⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Brigham and Women’s Hospital, Boston, MA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a post-hoc analysis of the tofacitinib RA long-term extension (LTE) studies,…
Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Matthew D. Cascino¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁶, Cees G.M. Kallenberg⁷, E. William St Clair⁸, Paul A. Monach⁹, John H. Stone¹⁰ and Paul Brunetta¹¹, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Mayo Clinic, Rochester, MN, ³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Duke University Medical Center, Durham, NC, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Genentech, Inc., South San Francisco, CA
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…
Abstract Number: 1973 • 2016 ACR/ARHP Annual Meeting
Intramuscular Versus Ultrasound Guided Peritendinous Glucocorticoid Injection for Tenosynovitis in Patients with Rheumatoid Arthritis – a Randomised, Double-Blind, Controlled Study
Mads Ammitzbøll-Danielsen^1,2, Mikkel Ostergaard^2,3, Viktoria Fana⁴, Daniel Glinatsi^2,5, Uffe Møller Døhn⁶, Lykke Midtbøll Ørnbjerg⁷, Esperanza Naredo⁸ and Lene Terslev⁶, ¹Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁵Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain
Background/Purpose: The aim of this study was to compare the efficacy of intramuscular versus ultrasound (US)-guided peritendinous glucocorticoid injection in providing disease control after…
Abstract Number: 2477 • 2016 ACR/ARHP Annual Meeting
Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
SA Bergstra¹, CF Allaart¹, R van den Berg¹, A Chopra², N Govind³, MJ Santos⁴, TWJ Huizinga⁵ and RBM Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Center for Rheumatic Diseases, Pune, India, Pune, India, ³Department of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa, ⁴Rheumatology, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ⁷Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) for newly diagnosed rheumatoid…
Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting
Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
Frank Buttgereit¹, Jonna Amann², Friederike Breitenfeldt³, Dörte Huscher⁴, Johannes WJ Bijlsma⁵ and Johannes WG Jacobs⁶, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ⁵ARC, Amsterdam, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…
Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting
The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Roy Fleischmann¹, Christina Charles-Schoeman², Gerd Burmester³, Cristiano Zerbini⁴, Peter Nash⁵, Kenneth Kwok⁶, Koshika Soma⁷, Alan Mendelsohn⁸ and Eustratios Bananis⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 1987 • 2015 ACR/ARHP Annual Meeting
Dramatic Efficacy of Tocilizumab As First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study
Valerie Devauchelle¹, Alain Saraux², Jean-Marie Berthelot³, Divi Cornec⁴, Yves Renaudineau⁵, Sandrine Jousse-Joulin¹, Thierry Marhadour⁶, Solene Querellou⁷, Florent Garrigues⁸, Michel De Bandt⁹ and Maelenn Gouillou¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, ²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ³Rheumatology, University Hospital, Nantes, France, ⁴Department of rheumatology, Brest Occidentale University, Brest, France, ⁵Immunology, Brest University Medical School Hospital, Brest, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Nuclear Medicine Department, Morvan University Hospital, Brest, France, ⁸Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁹Rheumatology department, CHU Fort de France, Fort de France, France, ¹⁰Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France
Background/Purpose: Glucocorticoids (GCs) are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce several adverse events. Methods: Objectives: To evaluate efficacy and safety of tocilizumab…
Abstract Number: 2235 • 2015 ACR/ARHP Annual Meeting
Shocking? a Systematic Review of Adrenal Insufficiency in Adults on Oral Steroids
Rebecca M Joseph¹, Louise Hunter², David W. Ray² and William G Dixon³, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: One percent of the adult population are, at any one time, prescribed oral glucocorticoids (GC). GCs are known to be associated with hypothalamic-pituitary-adrenal axis…
Abstract Number: 2653 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis
Uta Kiltz¹, Christine von Zabern¹, Xenofon Baraliakos¹, Frank Heldmann¹, Bernhard Mintrop¹, Michael Sarholz¹, Martin van Werde¹, Claudia Klink², Dietmar Krause², Friedrich Dybowski³, Ludwig Kalthoff³, Liane Hein³ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Private rheumatology office, Gladbeck, Germany, ³Private rheumatology office, Herne, Germany
Background/Purpose: In patients with tender and swollen finger joints, the differential diagnosis between rheumatoid arthritis (RA) and osteoarthritis (OA) of the hands can be initially…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].